The probe is legitimate in form; the question is whether it is sound in substance

According to CNBC, U.S. Trade Representative Jamieson Greer has opened a tariff investigation targeting Germany's pharmaceutical pricing policies, calling Berlin's proposed spending reductions on medicines "a serious step backwards." The mechanism being employed — a trade probe — is a lawful exercise of the federal commerce power. On that point I have no quarrel. The Constitution vests in Congress the power to regulate commerce with foreign nations, and the executive, acting under delegated authority, may properly investigate market conditions that distort American trade.

But legality and wisdom are not the same thing. I argued in the Reports on Manufactures that a strong industrial base — what we now call the pharmaceutical and biotech sector — is not a luxury but a pillar of national independence. A country that cannot produce its own medicines is as dependent as one that cannot arm itself. If German pricing policy genuinely suppresses returns to American manufacturers and thereby undermines investment in that industrial base, the probe has a principled commercial foundation. That is the argument worth making explicitly and loudly, because it is the argument that survives scrutiny.

What I would press the administration to clarify, however, is the theory of remedy. A tariff probe is an instrument of leverage; leverage is only as useful as the outcome it is designed to produce. If the goal is a bilateral agreement that opens German markets to American pharmaceutical exports on fair terms, say so. If the goal is to recover pricing power for American manufacturers, say so and model the numbers. Public credit — and I use the phrase broadly to mean public trust in the coherence of government action — depends on the government appearing to know what it wants before it acts.

I will confess humility on the precise mechanics of modern pharmaceutical pricing, the structure of European formularies, and the engineering of global supply chains — these are matters that postdate my own experience. But the durable principle is this: the federal commerce power must be construed broadly enough to make a national market and to defend it against foreign practices that hollow out American productive capacity. That principle supports the probe, at least in theory.

The risk I see — and I mark this as inference, not recollection — is that trade investigations launched without a clear terminal condition become instruments of political signaling rather than commercial policy. A nation that is seen to deploy its most powerful economic levers casually pays a credibility cost that compounds, much as a borrower who rattles the sword without striking loses the respect of both friend and rival. My recommendation: publish the theory of harm, publish the remedy sought, and prosecute the probe with energy and transparency. Commerce is not theater. The strength of the national industrial base is too serious a matter to be managed as a diplomatic gesture.